




Chemistry & Biology 2000, 7:R223^R224
1074-5521 / 00 / $ ^ see front matter ß 2000
Elsevier Science Ltd. All rights reserved.
PII: S 1 0 7 4 - 5 5 2 1 ( 0 0 ) 0 0 0 4 8 - X
Common anti-cancer drugs remain
crude, killing any cell that divides
rapidly. Onyx Pharmaceuticals, Inc.
(Richmond, CA, USA) hopes to
change that situation by targeting only
cells with the sorts of genetic defects
characteristic of cancer cells.
Onyx’s weapon, ONYX-015, is a
modi¢ed adenovirus (cold virus) that
lacks the E1B-55K gene. Without
E1B-55K, ONYX-015 can no longer
inactivate the cellular p53 protein, and
so cannot replicate in normal cells.
But, in tumor cells that lack p53,
ONYX-015 does just ¢ne. It can
replicate, and kill, the cancer cells.
ONYX-015 is exhibit A in an
emerging pack of replication-selective
viruses, which are ¢nding favor with
many gene therapists. ‘‘It is a very,
very important strategy to follow,’’
says Michael Blaese, head of human
therapeutics at ValiGen (US), Inc.
(Newtown, PA, USA) and former
chief of the clinical gene therapy
branch of the National Human
Genome Research Institute
(Bethesda, MD, USA). ‘‘The
traditional dead viruses used for gene
therapy simply will not work very well
because they cannot get around that
well.’’
But exhibit A is having its
problems. Since its triumphant
unveiling in 1996, ONYX-015 has
been plagued by doubts about
whether the virus’ ability to replicate
correlates with the status of the p53
pathway. Despite a recent paper from
Onyx’s founder, the ultimate verdict
may have to wait for the results of
ongoing clinical trials.
Company ¢rst, idea second
Before Onyx there was Chiron, and
before Chiron there was Cetus.
Both Onyx’s scienti¢c founder
Frank McCormick and its current
CEO Hollings Renton started out at
Cetus Corporation before moving to
Chiron Corporation (Emeryville, CA,
USA) when Chiron acquired Cetus. In
1992, McCormick says he ‘‘was
approached by some venture
capitalists, who convinced me that this
would be a good time to start my own
company. I was very happy in the job
that I already had, but they made me
an offer I could not refuse.’’
McCormick took his research
interest in ras signaling with him. At
the new company ‘‘the science was
not very different,’’ he says. ‘‘But
building something from the ground
up was very exciting.’’
Onyx’s therapy discriminates based
on the genetic changes that de¢ne
a cancer cell.
Soon after Onyx began,
McCormick attended a conference
where an adenovirus protein called
E1A was a major topic of conversation.
E1A was proposed to act in the same
manner as E1B-55K, but its target
seemed to be the tumor suppressor
Rb rather than p53. So far the major
evidence for this role was that E1A
and Rb bound to each other. But,
asked McCormick, ‘‘what was the
formal proof that Rb was the major
target?’’ Viruses with a mutant E1A
that could no longer bind Rb should
be replication-defective, but that
replication failure could also be
caused by another, unknown
consequence of the mutation.
‘‘I was trying to think of a better
way to prove that Rb is the major
target,’’ says McCormick. ‘‘I realized
there are cell lines that lack Rb, so
adenovirus would not need E1A any
more. Then I realized, if that were
true, the adenovirus without E1A
should only be able to replicate in
tumor cells (that lack Rb). The same
is true for E1B-55K and p53. As well
as being a really good experiment this
could lead to a therapeutic.’’
‘‘I could not wait to get to work the
next morning and bounce (the idea)
off my colleagues,’’ he says. Within a
few months he had a team of
virologists working on the problem,
using a virus from which Arnie Berk
(University of California, Los
Angeles, CA, USA) had deleted E1B-
55K. ‘‘The advantage of being
founder of the company,’’ says
McCormick, ‘‘is I could marshall the
resources to quickly test this out.’’
Success turns to doubt
Three years later McCormick had a
paper in Science. Richard Klausner,
director of the National Cancer
Institute (Bethesda, MD, USA),
hailed the discovery of such a cancer-
speci¢c virus as ‘‘a long-held fantasy.’’
But almost immediately there were
signs of discord. Berk drew attention
to old data indicating that
adenoviruses mutant for E1B-55K
could replicate in some cells
containing functional p53, and not in
some cells that lacked p53. This lack
of correlation led Berk to suggest that
‘‘the story is much more
complicated.’’
The Onyx researchers admitted as
much in their next publication the
following year. Killing by ONYX-015
was still restricted to cancer cells, but
not all of the susceptible cancer cells
were defective in p53.
A £ood of similar observations
followed from other laboratories in
1998 and 1999. ‘‘I was very worried,’’
says McCormick. ‘‘The lack of
correlation with p53 status was a
concern.’’ But McCormick felt the
answer was waiting. ‘‘We were pretty
convinced that the cells were ¢nding
other ways to knock out the (p53)
pathway,’’ he says. ‘‘Until we could
identify these we were on thin ice.’’
In the meantime, the criticisms
kept piling up. ‘‘The worst part about
it was that some of my colleagues
were really quite abusive,’’ says
McCormick. ‘‘It was not a very
objective discussion. It was quite
hostile.’’ David Ornelles of Wake
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Forest University (Winston-Salem,
NC, USA) stumbled into the dispute
when he started using the viruses for
his unrelated research. ‘‘I think,’’ he
says, ‘‘that there was an element of
human ego that elevated this above
and beyond what the science
justi¢ed.’’
McCormick responded with a paper
in the October 2000 issue of Nature
Medicine. He concluded that ONYX-
015 could replicate in a colorectal
cancer cell line that had an intact p53
gene because the cell line did not
express functional p14ARF. This
protein is an inhibitor of an inhibitor
of p53. Viral and other proliferative
signals normally induce p14ARF
expression, which frees up p53.
Adenovirus presumably needs E1B-
55K to counteract this newly liberated
p53. But in the cancer cells, the lack of
p14ARF meant that p53 was not
liberated and E1B-55K was no longer
needed. (This is despite the fact that
an intersecting pathway ^ from
irradiation to p53 to transcriptional
induction of p53 targets ^ was
completely intact in the same cell
line.)
McCormick showed that a number
of other p53+ cell lines that support
ONYX-015 replication also had
p14ARF defects, and reintroduction of
wild-type p14ARF suppressed ONYX-
015 replication. Onyx’s senior vice
president of research and
development Leonard Post thinks
this will answer many of the critics. ‘‘I
do not know that we can say that
(p14ARF) explains all of it,’’ he says.
‘‘It explains a lot of it.’’
McCormick is even more con¢dent.
‘‘I presume,’’ he says, ‘‘that the
controversy about p53 status is now
behind us.’’
But on it goes
Antony Braithwaite (University of
Otago, Dunedin, New Zealand) is not
so sure.
McCormick began his adenovirus
odyssey trying to con¢rm the function
of an adenovirus protein. He now uses
the presumed function of E1B-55K,
which is supported by the results of
transfection experiments, as one of his
defenses. The status of the p53
pathway must be important, he says,
because ‘‘the virus would not have a
protein (E1B-55K) to inactivate p53 if
it did not have to.’’
But Braithwaite is proposing that
E1B-55K has an entirely different, if
still p53-related function. He thinks
that a complex of p53, E1B-55K, and
another protein called E4orf6
regulates the cell cycle so that virus
replication and cell death are correctly
coordinated. ‘‘The complex is
regulating the cell replication
machinery to maximize (virus)
production, then it is utilizing a point
of sensitivity in the cell cycle to
induce cell death,’’ says Braithwaite.
‘‘That is the theory. I have not got all
the data to prove that yet.’’
What Braithwaite claims to have
shown is that p53 is necessary for
maximal viral replication and rapid
cell death. Both replication and death
can occur without p53, he says, but
they are less extensive and slower. In
a Cancer Research paper in May 2000,
Braithwaite reported that the failure of
the rapid cell death pathway is
correlated with the presence of E1B-
55K mutants that cannot bind p53.
Braithwaite cannot yet explain how
the Onyx virus selectively kills
transformed cells. And it is dif¢cult to
compare his work to that of
McCormick, as Braithwaite’s readout
is cell death rather than the more
usual replication measure of plaque-
forming units.
McCormick, meanwhile, says he
‘‘agree(s) with (Braithwaite’s)
proposition that the E1B-55K/E4orf6
complex may have unknown and
important roles in virus replication.
However, these functions are
independent of p53. After all, as
dozens of papers have described, p53
is actively degraded during
adenovirus infection.’’
The proof is in the phase III trial
Braithwaite thinks a compromise may
be possible. ‘‘We appear to be at
opposite poles from Onyx and
others,’’ he says. But ‘‘the differences
may be quantitative rather than
qualitative.’’
The ¢nal verdict may come from
Onyx’s phase III trial for head and
neck cancer. The phase II trial,
combining ONYX-015 with
chemotherapy, ‘‘gave us a great deal
of con¢dence,’’ says CEO Renton.
Nineteen of thirty patients with
advanced tumors showed 50% or
greater response to therapy.
Clinical trials and the debate about
mechanism coincided. ‘‘It did not
slow us down,’’ says Renton. ‘‘As long
as (ONYX-015) had a good strong
therapeutic index we wanted to go
ahead.’’ The trials showed no
correlation between treatment success
and p53 status, although p14ARF
function was not measured. In the
phase III trials ‘‘the idea is to take all
comers and retrospectively analyze
who does best,’’ says McCormick.
Side effects have been minimal so
far, perhaps because the selectively
replicating virus can be used at lower
doses than traditional non-replicating
gene therapy vectors. One ‘‘legitimate
concern,’’ according to McCormick,
was apoptosis of normal cells in
response to even a non-productive
infection. In culture ONYX-015
induces a signi¢cant amount of cell
death, but whatever cell death occurs
in vivo does not appear to be a
problem.
Also ongoing are phase II trials for
multiple cancer types, and a phase I
trial using intravenous delivery (other
trials involve direct injection into
tumors). Onyx is designing new
viruses ^ viruses that will make
prodrug-converting enzymes, and
viruses targeted to receptors on tumor
cells ^ in the hope that these viruses
will have an even greater selective
advantage. ‘‘The kind of results we
are getting are as exciting as anything
else in cancer therapy,’’ says
McCormick, ‘‘and we are just
starting.’’
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